LXRX vs. VSTM, VNDA, XOMA, EBS, RIGL, RGLS, RZLT, OPK, INVA, and IRWD
Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Verastem (VSTM), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Emergent BioSolutions (EBS), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), Rezolute (RZLT), OPKO Health (OPK), Innoviva (INVA), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.
Verastem (NASDAQ:VSTM) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation.
Verastem has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.
Verastem has a net margin of 0.00% compared to Verastem's net margin of -8,311.12%. Verastem's return on equity of -108.54% beat Lexicon Pharmaceuticals' return on equity.
Verastem received 132 more outperform votes than Lexicon Pharmaceuticals when rated by MarketBeat users. Likewise, 65.25% of users gave Verastem an outperform vote while only 64.58% of users gave Lexicon Pharmaceuticals an outperform vote.
In the previous week, Verastem had 21 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 24 mentions for Verastem and 3 mentions for Lexicon Pharmaceuticals. Verastem's average media sentiment score of 1.87 beat Lexicon Pharmaceuticals' score of 0.15 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.
Verastem has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.
88.4% of Verastem shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 2.2% of Verastem shares are owned by insiders. Comparatively, 4.5% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Verastem currently has a consensus price target of $26.50, indicating a potential upside of 517.72%. Lexicon Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 197.62%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Verastem is more favorable than Lexicon Pharmaceuticals.
Summary
Verastem beats Lexicon Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Lexicon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexicon Pharmaceuticals Competitors List
Related Companies and Tools
